Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Payables (2016 - 2025)

Jaguar Health (JAGX) has disclosed Payables for 11 consecutive years, with $31.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 96.71% to $31.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $31.6 million, a 96.71% increase, with the full-year FY2024 number at $17.3 million, up 76.04% from a year prior.
  • Payables was $31.6 million for Q3 2025 at Jaguar Health, up from $25.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $31.6 million in Q3 2025 to a low of $5.6 million in Q3 2021.
  • A 5-year average of $15.4 million and a median of $15.2 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 57.3% in 2021, then soared 223.73% in 2022.
  • Jaguar Health's Payables stood at $8.1 million in 2021, then skyrocketed by 167.36% to $21.7 million in 2022, then plummeted by 54.63% to $9.8 million in 2023, then surged by 76.04% to $17.3 million in 2024, then skyrocketed by 82.12% to $31.6 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Payables are $31.6 million (Q3 2025), $25.2 million (Q2 2025), and $25.7 million (Q1 2025).